Education
About Us
Working with TipRanks
Follow Us
MaxCyte Inc (GB:MXCT)
LSE:MXCT
MXCT Stock Chart & Stats
Day’s Range― - ―
52-Week Range206.00p - 410.00p
Previous CloseN/A
Volume8.70K
Average Volume (3M)27.97K
Market Cap
£224.04M
Enterprise Value273.36M
Total Cash (Recent Filing)$27.88M
Total Debt (Recent Filing)$18.03M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
May 13, 2025EPS Estimate
-8.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding106,027,730
10 Day Avg. Volume27,615
30 Day Avg. Volume27,967
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)8.48
Price to Cash Flow (P/CF)-10.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.22
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.67
Enterprise Value/Ebitda-5.89
Forecast
1Y Price Target
580.50pPrice Target Upside176.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
MaxCyte News
PremiumCompany Announcements
MaxCyte Expands Capital with New Stock Issuance
PremiumCompany Announcements
MaxCyte Announces CFO’s RSU Vesting and Share Sale
PremiumCompany Announcements
MaxCyte Announces CFO’s RSU Vesting and Share Sale---
Bulls Say, Bears Say
Bulls Say
Financial StabilityFY24 cash of $185M provides multi-year support for the company's growth and initiatives.
Revenue GrowthMXCT delivered a record 6 SPL agreements in 2024 and ended 2024 with 28 active SPL agreements, including 18 that are active in the clinic and one that is commercial.
Strategic InitiativesNew product launches represent upside opportunities to organic growth guidance.
Bears Say
Market ConditionsMXCT views the cell therapy funding market as 'stabilizing', but has not fully improved, and that customers continue to have a cautious capital-spending mindset.
Revenue GuidanceThe 2025 revenue guide was lower than expected, particularly for core organic growth.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.31% Insiders
14.17%
Mutual Funds
33.13% Other Institutional Investors
40.86% Public Companies and
Individual Investors
MXCT FAQ
What was MaxCyte Inc’s price range in the past 12 months?
MaxCyte Inc lowest share price was 206.00p and its highest was 410.00p in the past 12 months.
What is MaxCyte Inc’s market cap?
MaxCyte Inc’s market cap is £224.04M.
When is MaxCyte Inc’s upcoming earnings report date?
MaxCyte Inc’s upcoming earnings report date is May 13, 2025 which is in 40 days.
How were MaxCyte Inc’s earnings last quarter?
MaxCyte Inc released its earnings results on Mar 11, 2025. The company reported -0.077p earnings per share for the quarter, beating the consensus estimate of -0.093p by 0.015p.
Is MaxCyte Inc overvalued?
According to Wall Street analysts MaxCyte Inc’s price is currently Undervalued.
Does MaxCyte Inc pay dividends?
MaxCyte Inc does not currently pay dividends.
What is MaxCyte Inc’s EPS estimate?
MaxCyte Inc’s EPS estimate is -8.2.
How many shares outstanding does MaxCyte Inc have?
MaxCyte Inc has 106,027,730 shares outstanding.
What happened to MaxCyte Inc’s price movement after its last earnings report?
MaxCyte Inc reported an EPS of -0.077p in its last earnings report, beating expectations of -0.093p. Following the earnings report the stock price went down -13.208%.
Which hedge fund is a major shareholder of MaxCyte Inc?
Currently, no hedge funds are holding shares in GB:MXCT
---
Company Description
MaxCyte Inc
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
---
MXCT Stock 12 Month Forecast
Average Price Target
580.50p
▲(176.43% Upside)
Technical Analysis
Sangamo Biosciences
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering MXCT
1 Year
1 Year Success Rate
5/20 ratings generated profit
1 Year Average Return
-15.92%
reiterated a buy rating 4 days ago
Copying Mark Massaro's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -15.92% per trade.
---